EMEA-001214-PIP01-11-M11 - paediatric investigation plan

Benralizumab

Key facts

• Invented name:
  Fasenra
• Active Substance:
  Benralizumab
• Therapeutic area:
  Pneumology-allergology
• Decision number:
  P/0129/2022
• PIP number:
  EMEA-001214-PIP01-11-M11
• Pharmaceutical form(s):
  Solution for injection
• Condition(s) / indication(s):
  Treatment of asthma
• Route(s) of administration:
  Subcutaneous use
• Decision type:
  PM: decision on the application for modification of an agreed PIP
• Decision date:
  13/04/2022

Decision

P/0129/2022 : EMA decision of 13 April 2022 on the acceptance of a modification of an agreed paediatric investigation plan for benralizumab (Fasenra), (EMEA-001214-PIP01-11-M11)

AdoptedReference Number: EMA/157570/2022